[New trends in non-Hodgkin's lymphoma therapy].
Non-Hodgkin's lymphomas are a heterogeneous group of lymphoid malignancies. Although great progress in the treatment of these diseases has been made in the last years, it is still difficult to achieve and sustain remission in different lymphoma subtypes and some of patients have poor prognosis. Apart from monoclonal antibodies, radioimmunotherapy, and autologous stem cell transplantation, which are used as standard therapy for some lymphomas, new drugs with different mechanism of action are currently being tested. This article describes new methods and drugs which are used in the treatment of non-Hodgkin's lymphomas.
Mazur
Grzegorz
G
Katedra i Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku Akademii Medycznej we Wrocławiu. grzegorzmaz@yahoo.com
Wróbel
Tomasz
T
Jurczak
Wojciech
W
Butrym
Aleksandra
A
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data / Q000639:trends; D018572:Disease-Free Survival; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000532:radiotherapy*; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D016499:Radioimmunotherapy / Q000639:trends*; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D007457:Iodine Radioisotopes; D011480:Protease Inhibitors; D015021:Yttrium Radioisotopes; D006655:Histone Deacetylases